[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201590503A1 - Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями - Google Patents

Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями

Info

Publication number
EA201590503A1
EA201590503A1 EA201590503A EA201590503A EA201590503A1 EA 201590503 A1 EA201590503 A1 EA 201590503A1 EA 201590503 A EA201590503 A EA 201590503A EA 201590503 A EA201590503 A EA 201590503A EA 201590503 A1 EA201590503 A1 EA 201590503A1
Authority
EA
Eurasian Patent Office
Prior art keywords
microglobulin
mitochondria
alpha
treatment
diseases associated
Prior art date
Application number
EA201590503A
Other languages
English (en)
Other versions
EA028963B1 (ru
Inventor
Бо Акерстрем
Магнус Грам
Лена Розенлеф
Original Assignee
А1М Фарма Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by А1М Фарма Аб filed Critical А1М Фарма Аб
Publication of EA201590503A1 publication Critical patent/EA201590503A1/ru
Publication of EA028963B1 publication Critical patent/EA028963B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к альфа-1-микроглобулину для применения в лечении заболевания, связанного с митохондриями.
EA201590503A 2012-09-05 2013-09-04 Применение альфа-1-микроглобулина для защиты митохондриальной структуры и/или митохондриальной продукции атф EA028963B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201270538 2012-09-05
DKPA201270557 2012-09-12
PCT/EP2013/068270 WO2014037390A1 (en) 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Publications (2)

Publication Number Publication Date
EA201590503A1 true EA201590503A1 (ru) 2015-06-30
EA028963B1 EA028963B1 (ru) 2018-01-31

Family

ID=49162118

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590503A EA028963B1 (ru) 2012-09-05 2013-09-04 Применение альфа-1-микроглобулина для защиты митохондриальной структуры и/или митохондриальной продукции атф

Country Status (21)

Country Link
US (1) US10226507B2 (ru)
EP (1) EP2900254B1 (ru)
JP (2) JP2015533790A (ru)
KR (1) KR20150047510A (ru)
CN (1) CN104661673A (ru)
AU (1) AU2013311714C1 (ru)
BR (1) BR112015003957A2 (ru)
CA (1) CA2881321A1 (ru)
DK (1) DK2900254T3 (ru)
EA (1) EA028963B1 (ru)
ES (1) ES2599034T3 (ru)
HR (1) HRP20161364T1 (ru)
HU (1) HUE030559T2 (ru)
IN (1) IN2015DN00515A (ru)
MX (1) MX357656B (ru)
NZ (1) NZ629621A (ru)
PL (1) PL2900254T3 (ru)
PT (1) PT2900254T (ru)
SG (1) SG11201500669SA (ru)
WO (1) WO2014037390A1 (ru)
ZA (1) ZA201500547B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016204360A (ja) * 2015-02-25 2016-12-08 エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン
WO2017144674A1 (en) * 2016-02-25 2017-08-31 A1M Pharma Ab Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media
SG11201807352XA (en) * 2016-03-18 2018-09-27 A1M Pharma Ab Novel alpha-1-microglobulin derived proteins and their use
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
CN110452980B (zh) * 2019-09-23 2023-07-28 武汉儿童医院 一种线粒体脑肌病诊断试剂盒及应用
US20220362293A1 (en) * 2019-09-25 2022-11-17 Cytegen Corp. Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products
CN115575646B (zh) * 2022-11-21 2023-04-28 四川大学华西医院 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004292775A1 (en) * 2003-11-26 2005-06-09 Sanofi-Aventis Deutschland Gmbh Tubular proteinuria as an indicator for elevated cardiovascular risk
EA031877B1 (ru) * 2007-02-12 2019-03-29 А1М Фарма Аб Применение альфа-1-микроглобулина для профилактики или лечения преэклампсии
HUE026750T2 (en) * 2008-02-04 2016-07-28 Yissum Res Dev Co Methods and Preparations for the Treatment of Mitochondrial Disorders
HUE030274T2 (en) * 2008-07-18 2017-05-29 A1M Pharma Ab The therapeutic use of the root binding and antioxidant alpha-1 microglobulin

Also Published As

Publication number Publication date
NZ629621A (en) 2015-09-25
EA028963B1 (ru) 2018-01-31
HK1210585A1 (en) 2016-04-29
AU2013311714A1 (en) 2015-03-12
SG11201500669SA (en) 2015-02-27
IN2015DN00515A (ru) 2015-06-26
BR112015003957A2 (pt) 2017-08-08
KR20150047510A (ko) 2015-05-04
ES2599034T3 (es) 2017-01-31
JP2015533790A (ja) 2015-11-26
AU2013311714B2 (en) 2017-10-12
HRP20161364T1 (hr) 2016-12-16
JP2018203756A (ja) 2018-12-27
PT2900254T (pt) 2016-10-18
US10226507B2 (en) 2019-03-12
US20150258171A1 (en) 2015-09-17
CN104661673A (zh) 2015-05-27
PL2900254T3 (pl) 2017-02-28
DK2900254T3 (en) 2016-08-29
EP2900254A1 (en) 2015-08-05
HUE030559T2 (en) 2017-05-29
MX2015002604A (es) 2015-06-10
ZA201500547B (en) 2017-09-27
MX357656B (es) 2018-07-18
CA2881321A1 (en) 2014-03-13
EP2900254B1 (en) 2016-08-03
WO2014037390A1 (en) 2014-03-13
AU2013311714C1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34885A (es) Proteínas de unión anti-mesotelina
JOP20200175A1 (ar) حقنة
EA201400178A1 (ru) Лечение рака молочной железы
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34817A (es) Tienopirimidinas
UY4234Q (es) Configuración aplicada en zapato
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
BR112015012907A2 (pt) composição de cuidado pessoal
UY34582A (es) Anticuerpos anti-cxcr3
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
UY33976A (es) Derivados de pirazolo-pirimidina.
UY34677A (es) Imidazopiridazinas sustituidas
BR112014028443A2 (pt) composição estéril.
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
UY4237Q (es) Taburete
UY4233Q (es) Configuración aplicada en zapato
UY34564A (es) Utilización en terapéutica de derivados de imidazopiridina
EA201401045A1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
FR2987092B1 (fr) Ensemble de reducteurs.
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
CL2012000641S1 (es) Lavamanos.
TN2011000162A1 (fr) نظام هندسي ومعماري مبتكر لانشاء البناء عامة ومواكب للتكنولوجيات المتطورة مادته الاساسية الطين والتربة
TN2011000372A1 (fr) جهاز مراقبة وتحكم في استهلاك المياه
TN2011000399A1 (fr) دراجة كهربائية ذات شحن الي

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU